Clinically distinct COVID-19 cases share notably similar immune response progression: A follow-up analysis. Issue 1 (January 2021)

• Record Type: Journal Article
• Authors: Hausburg, Melissa A.; Banton, Kaysie L.; Roshon, Michael; Bar-Or, David
• Is Part Of: Heliyon. Volume 7:Issue 1(2021)
• Publication Date: 2021-01
• Subjects: SARS-CoV-2 -- COVID-19 -- SERPING1 -- Complement -- B cell -- Interferon -- MHC class II; Research -- Periodicals; Medical sciences -- Periodicals; Natural history -- Periodicals; Social sciences -- Periodicals; Earth sciences -- Periodicals; Physical sciences -- Periodicals; 507.2
• DOI: 10.1016/j.heliyon.2020.e05877
• Languages: English
• ISSNs: 2405-8440

Abstract

Abstract: Inflammatory responses to the novel coronavirus SARS-CoV-2, which causes COVID-19, range from asymptomatic to severe. Here we present a follow-up analysis of a longitudinal study characterizing COVID-19 immune responses from a father and son with distinctly different clinical courses. The father required a lengthy hospital stay for severe symptoms, whereas his son had mild symptoms and no fever yet tested positive for SARS-CoV-2 for 29 days. Father and son, as well as another unrelated COVID-19 patient, displayed a robust increase of SERPING1, the transcript encoding C1 esterase inhibitor (C1–INH). We further bolstered this finding by incorporating a serum proteomics dataset and found that serum C1–INH was consistently increased in COVID-19 patients. C1–INH is a central regulator of the contact and complement systems, potentially linking COVID-19 to complement hyperactivation, fibrin clot formation, and immune depression. Furthermore, despite distinct clinical cases, significant parallels were observed in transcripts involved in interferon and B cell signaling. As symptoms were resolving, widespread decreases were seen in immune-related transcripts to levels below those of healthy controls. Our study provides insight into the immune responses of likely millions of people with extremely mild symptoms who may not be aware of their infection with SARS-CoV-2 and implies a potential for long-lasting consequences that could contribute to reinfection risk. Abstract : SARS-CoV-2; COVID-19; SERPING1; Complement; B cell; Interferon; MHC class II